Brokers Issue Forecasts for LMAT FY2025 Earnings

LeMaitre Vascular, Inc. (NASDAQ:LMAT) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of LeMaitre Vascular in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the medical instruments supplier will post earnings per share of $2.22 for the year. Cantor Fitzgerald has a “Neutral” rating and a $96.00 price objective on the stock. The consensus estimate for LeMaitre Vascular’s current full-year earnings is $1.94 per share.

A number of other equities research analysts also recently weighed in on LMAT. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Oppenheimer reiterated an “outperform” rating and issued a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Barrington Research increased their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $94.57.

LeMaitre Vascular Trading Down 1.7 %

LMAT stock opened at $96.31 on Wednesday. LeMaitre Vascular has a 1-year low of $56.04 and a 1-year high of $109.58. The stock has a 50-day moving average price of $98.18 and a 200-day moving average price of $92.23. The firm has a market cap of $2.17 billion, a PE ratio of 52.63, a price-to-earnings-growth ratio of 2.19 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular’s quarterly revenue was up 15.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.33 earnings per share.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 3,750 shares of LeMaitre Vascular stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total transaction of $380,512.50. Following the completion of the transaction, the director now owns 2,278 shares in the company, valued at approximately $231,148.66. The trade was a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. NBC Securities Inc. raised its position in LeMaitre Vascular by 73.2% in the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 183 shares during the last quarter. USA Financial Formulas purchased a new stake in shares of LeMaitre Vascular in the third quarter valued at about $60,000. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 34.3% during the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock valued at $68,000 after purchasing an additional 188 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in LeMaitre Vascular during the second quarter worth about $82,000. Finally, KBC Group NV grew its position in LeMaitre Vascular by 58.4% in the 4th quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.